LYVE1 antibody

Catalog No. ABIN289493

Product Details anti-LYVE1 Antibody

Target: LYVE1 (Lymphatic Vessel Endothelial Hyaluronan Receptor 1 (LYVE1))

Reactivity: Mouse

Host: Rabbit

Clonality: Polyclonal

Conjugate: This LYVE1 antibody is un-conjugated

Application: Western Blotting (WB), ELISA, Flow Cytometry (FACS)

Purification: Protein A affinity chromatography

Immunogen: LYVE1 antibody was raised in rabbit using recombinant mouse soluble Lyve-1 as the immunogen.

Isotype: IgG

Application Details

Application Notes: ELISA: 1-15 µg/mL, FC: 3-10 µg/mL, WB:2-5 µg/mL
Optimal conditions should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Concentration: Lot specific

Buffer: Supplied in lyophilized formin PBS buffer

Handling Advice: Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use.

Storage: 4 °C/-20 °C

Storage Comment: Store at -20 °C until reconstitution. Following reconstitution product may be stored at 4 °C in the short term. For long term storage aliquot and freeze at -20 °C.

References for anti-LYVE1 antibody (ABIN289493)

Piao, Xiong, Li, Saxena, Smith, Hippen, Paluskievicz, Willsonshirkey, Blazar, Abdi, Bromberg: "Regulatory T Cells Condition Lymphatic Endothelia for Enhanced Transendothelial Migration." in: Cell reports, Vol. 30, Issue 4, pp. 1052-1062.e5, (2020) (PubMed).

Bourland, Fradette, Auger: "Tissue-engineered 3D melanoma model with blood and lymphatic capillaries for drug development." in: Scientific reports, Vol. 8, Issue 1, pp. 13191, (2019) (PubMed).

Piao, Xiong, Famulski, Brinkman, Li, Toney, Wagner, Saxena, Simon, Bromberg: "Regulation of T cell afferent lymphatic migration by targeting LTβR-mediated non-classical NFκB signaling." in: Nature communications, Vol. 9, Issue 1, pp. 3020, (2018) (PubMed).

Le, Nowell, Kim-Fuchs, Botteri, Hiller, Ismail, Pimentel, Chai, Karnezis, Rotmensz, Renne, Gandini, Pouton, Ferrari, Möller, Stacker, Sloan: "Chronic stress in mice remodels lymph vasculature to promote tumour cell dissemination." in: Nature communications, Vol. 7, pp. 10634, (2016) (PubMed).

Brinkman, Iwami, Hritzo, Xiong, Ahmad, Simon, Hippen, Blazar, Bromberg: "Treg engage lymphotoxin beta receptor for afferent lymphatic transendothelial migration." in: Nature communications, Vol. 7, pp. 12021, (2016) (PubMed).

Stefanini, Paul, Robledo, Chan, Getz, Campbell, Kechele, Casari, Piatt, Caron, Mackman, Weyrich, Parrott, Boulaftali, Adams, Peters, Bergmeier: "RASA3 is a critical inhibitor of RAP1-dependent platelet activation." in: The Journal of clinical investigation, Vol. 125, Issue 4, pp. 1419-32, (2015) (PubMed).

Owens, Pickup, Novitskiy, Giltnane, Gorska, Hopkins, Hong, Moses: "Inhibition of BMP signaling suppresses metastasis in mammary cancer." in: Oncogene, Vol. 34, Issue 19, pp. 2437-49, (2015) (PubMed).

Yücel, Johnston, Ly, Patel, Drake, Gümüş, Fraenkl, Moore, Tobbia, Armstrong, Horvath, Gupta: "Identification of lymphatics in the ciliary body of the human eye: a novel "uveolymphatic" outflow pathway." in: Experimental eye research, Vol. 89, Issue 5, pp. 810-9, (2009) (PubMed).

Target Details for LYVE1

Target: LYVE1 (Lymphatic Vessel Endothelial Hyaluronan Receptor 1 (LYVE1))

Alternative Name: LYVE1 (LYVE1 Products)

Background: LYVE-1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. The deduced amino acid sequence of LYVE-1 predicts a 322-residue type I integral membrane polypeptide 41% similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module the prototypic HA binding domain of the Link protein superfamily.

Pathways: Glycosaminoglycan Metabolic Process